Published in:
01-10-2019 | Original Article
Irisin as a Novel Marker for Insulin Resistance in Iraqi Women with Polycystic Ovary Syndrome Before and After Metformin Therapy
Published in: The Journal of Obstetrics and Gynecology of India | Special Issue 2/2019
Login to get accessAbstract
Background
Polycystic ovarian syndrome affects 5–10% of women; it represents the most common cause of hyperinsulinemia with anovulation. Many biomarkers are used to assess insulin resistance. Irisin is a newly discovered myokine associated with insulin resistance and other metabolic syndromes.
Objective
To measure the serum level of irisin in polycystic ovary syndrome patients and assess the effect of metformin treatment on its level.
Method
This study was a prospective interventional study conducted in a private clinic and Al-Yarmouk Teaching Hospital in Baghdad City from January 1, 2017, till April 1, 2018. A hundred women were enrolled in the study. Fifty of them suffered from PCOS and other fifty were normal. They were randomly selected according to computer-based randomization and assigned as a control group. Hormonal, biochemical and oral glucose tolerance tests were performed on all patients, including Irisin. The results have been compared for both groups. Twenty-nine women of PCOS patients received metformin for a course period of 4 months as the changes in their biochemical results were evaluated.
Result
Serum irisin level was higher in patients group compared to control group (312 ± 134.3 and 188.4 ± 53.8 μg/l, respectively), and the difference was statistically significant as the p value < 0.001. After 4 months treatment with metformin for twenty-nine polycystic patients, there was a significant reduction in irisin level by (165.8 ± 55.6 μg/l) and the p value was significant.
Conclusion
Irisin might be used as a simple test for the prediction of insulin resistance in PCOS patients.